Search - tctmd.com

Displaying 141 - 160 of 274

Sort: Relevancy | Date

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

News Conference News HRS 2022

Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era

May 02, 2022

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

News Daily News

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

April 20, 2022

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

News Daily News

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

April 15, 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

News Conference News ACC 2022

METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF

April 08, 2022

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

News Conference News ACC 2022

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

April 03, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

Prognosis of Myocarditis Following COVID-19 Vaccination ‘Favorable’

News Daily News

Prognosis of Myocarditis Following COVID-19 Vaccination ‘Favorable’

Michael O'Riordan

March 28, 2022

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

March 22, 2022

Familial Patterns of Idiopathic Dilated Cardiomyopathy Becoming Clearer

News Daily News

Familial Patterns of Idiopathic Dilated Cardiomyopathy Becoming Clearer

February 10, 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

February 07, 2022

LAVA ECMO: Early Data Point to Hemodynamic Benefits, Safety

News Conference News THT 2022

LAVA ECMO: Early Data Point to Hemodynamic Benefits, Safety

February 02, 2022

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

News Daily News

CABG Provides ‘Good Value’ in Ischemic Cardiomyopathy

January 26, 2022

Cardiac Abnormalities Seen After COVID-19, but Recovery Is Quick

News Daily News

Cardiac Abnormalities Seen After COVID-19, but Recovery Is Quick

Michael O'Riordan

January 20, 2022

Extended DANISH Follow-up Supports ICD Benefits in Younger Nonischemic HF Patients

News Daily News

Extended DANISH Follow-up Supports ICD Benefits in Younger Nonischemic HF Patients

December 14, 2021

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 07, 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

News Conference News AHA 2021

Risk-Based EHR Alert Doesn’t Improve HF Care or Outcomes: REVEAL-HF

Michael O'Riordan

November 19, 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

November 17, 2021

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

News Conference News

Trial of Cell Therapy for HF Misses Primary Endpoint, but Signals a Path Forward

November 16, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.